PT - JOURNAL ARTICLE AU - Wanaratna, Kulthanit AU - Leethong, Pornvimol AU - Inchai, Nitapha AU - Chueawiang, Wararath AU - Sriraksa, Pantitra AU - Tabmee, Anutida AU - Sirinavin, Sayomporn TI - Efficacy and safety of <em>Andrographis paniculata</em> extract in patients with mild COVID-19: A randomized controlled trial AID - 10.1101/2021.07.08.21259912 DP - 2021 Jan 01 TA - medRxiv PG - 2021.07.08.21259912 4099 - http://medrxiv.org/content/early/2021/08/19/2021.07.08.21259912.short 4100 - http://medrxiv.org/content/early/2021/08/19/2021.07.08.21259912.full AB - Objectives To assess the efficacy and safety of Andrographis paniculata extract (APE) in adults with mild COVID-19.Methods Sixty-three adults aged 18-60 years, without co-morbidity, with laboratory-confirmed mild COVID-19, were randomized 1:1 to receive APE (60 mg andrographolide, t.i.d, for 5 days) or placebo within 24 hours after admission, plus standard supportive care. The outcomes were clinical recovery rates by Day 5 using self-assessment scores, pneumonia by chest X-rays, nasopharyngeal SARS-CoV-2 detection by rRT-PCR on Day 5, changes of serum CRP levels, and adverse drug reactions. Chest X-rays and blood tests for CRP, liver and renal function, were performed on Days 1, 3, and 5.Results Baseline characteristics of patients in the APE-treatment (n=29) and placebo-control (n=28) groups were comparable. None had self-assessment scores showing complete clinical recovery by Day 5. Pneumonia occurred in 0/29 (0%) versus 3/28 (10.7%), (p=0.112). On Day 5, patients with SARS-CoV-2 detection were 10/29 (34.5%) versus 16/28 (57.1%), (p=0.086); patients with CRP &gt;10 mg/L were 0/29 (0%) versus 5/28 (17.9%), (p=0.023), for APE-treatment and placebo-control groups, respectively. All three patients with pneumonia had substantially rising serum CRP; and high CRP levels on Day 5. None had evidence of hematologic, hepatic or renal impairment.Conclusion Even though the study was limited by small sample size, our findings suggested promising efficacy and safety of the APE-treatment regimen in adults with mild COVID-19. Further studies, with adequate power to assure these findings, are required.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialTCTR20210708001Funding StatementThe trial was supported by Thai Traditional Medical Knowledge Fund.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial was approved by the Ethics Committee for Research in Human Subjects in the Fields of Thai Traditional and Alternative Medicine, Thailand (No.12-2563).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesManuscript Number: THEIJID-D-21-01999 Article Title: Efficacy and safety of Andrographis paniculata extract in patients with mild COVID-19: A randomized controlled trial. International Journal of Infectious Diseases. On Peer review process.